Hassan MM - Search Results

1

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.

Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Hassan MM, et al. Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800. Online ahead of print. Hepatology. 2024. PMID: 38381705

2

Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma.

Wu X, Gu J, Patt Y, Hassan M, Spitz MR, Beasley RP, Hwang LY. Wu X, et al. Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):567-70. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9681523

3

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.

Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Patt YZ, et al. Among authors: hassan mm. Am J Clin Oncol. 2000 Jun;23(3):319-21. doi: 10.1097/00000421-200006000-00023. Am J Clin Oncol. 2000. PMID: 10857902

4

The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients.

Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY. Hassan MM, et al. J Clin Gastroenterol. 2001 Aug;33(2):123-6. doi: 10.1097/00004836-200108000-00006. J Clin Gastroenterol. 2001. PMID: 11468438

5

Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.

Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D. Firozi PF, et al. Among authors: hassan mm. Carcinogenesis. 2002 Feb;23(2):301-6. doi: 10.1093/carcin/23.2.301. Carcinogenesis. 2002. PMID: 11872636

6

Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States.

Hassan MM, Frome A, Patt YZ, El-Serag HB. Hassan MM, et al. J Clin Gastroenterol. 2002 Sep;35(3):266-9. doi: 10.1097/00004836-200209000-00013. J Clin Gastroenterol. 2002. PMID: 12192205

7

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.

Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Hassan MM, et al. Hepatology. 2002 Nov;36(5):1206-13. doi: 10.1053/jhep.2002.36780. Hepatology. 2002. PMID: 12395331

8

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM. Patt YZ, et al. Among authors: hassan mm. J Clin Oncol. 2003 Feb 1;21(3):421-7. doi: 10.1200/JCO.2003.10.103. J Clin Oncol. 2003. PMID: 12560429 Clinical Trial.

9

Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis.

Ghalib R, Levine C, Hassan M, McClelland T, Goss J, Stribling R, Seu P, Patt YZ. Ghalib R, et al. Hepatology. 2003 May;37(5):1165-71. doi: 10.1053/jhep.2003.50160. Hepatology. 2003. PMID: 12717398 Clinical Trial.

10

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.

Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD. Patt YZ, et al. Among authors: hassan mm. Cancer. 2004 Aug 1;101(3):578-86. doi: 10.1002/cncr.20368. Cancer. 2004. PMID: 15274071 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

725 results

Search Page